Obermatt
See Similar Stocks →

Flags

Financial distress

Aprogen Biologics

KSC:003060 · KR7003060001
PharmaceuticalsX-Small

360

10
Medium confidence — indicative
Profit price47
Owner Earnings Yield1
Dividend Yield1
Price/Sales73
Price/Book100
Return on Capital30
Cash Return on Capital18
Return on Equity25
EBIT Margin1
Gross Profitability4
Accruals75
Owner Earnings Margin5
Sales growth92
Profit growth13
Reinvestment16
Price momentum1
Debt load17
Refinancing96
Debt Payback1
Liquidity8
Analyst ratings—
Expectations trend—
Market mood1
Value Creation6/20not creating value
  • Creates more value than its capital costs
  • Owner earnings growing
  • Owner earnings per share growing
  • Reinvests at strong returns
  • Solid earnings base

What this means

Aprogen Biologics doesn't consistently earn more than its cost of capital, so it isn't yet creating shareholder value.

Profile

CountrySouth Korea
IndustryPharmaceuticals
SizeX-Small
TypePublic Company
ExchangeKOSE
Websiteaprogen-pharm.com
ISINKR7003060001
Last UpdateApr 2, 2026
Indices
KOSPI (South Korea)
Themes
Pharmaceutical

Description

Analysis

Weak and unloved

Aprogen Biologics Inc. scores below average on quality and is priced accordingly, a low-conviction position in either direction.

Valuation data is not available for this company.

Growth is mixed; the safety picture is stretched. The company scores 6/20 on our value-creation score: not creating value.

No flags apply to this company at this time: accounts, balance sheet, and cash quality all pass. A clean bill of health is meaningful, not just the absence of a warning. This analysis describes numbers; it is not investment advice.

360° rank · history

1007550250
1
2026

All-time high

10

Mar 2026

All-time low

1

Jun 2026

Average rank

6

across all years

Detailed & Historical Ranks

Deep dive into 15 detailed ranks and 3 years of history.

Current202520242023
Price/Sales
73
—
—
—
Price/Earnings
—
—
—
—
Price/Book
100
—
—
—
Dividend Yield
1
—
—
—
Value (overall)
57
—
—
—

Cells are coloured by rank band (red weak → green strong). Sentiment & 360° history begins 2023.

Similar Stocks

The companies this stock is ranked against.

Compare Aprogen Biologics with its peers
Whanin Pharm
KSC:016580
99
CountrySouth Korea
IndustryPharmaceuticals
SizeSmall
Full Stock Analysis →
Daewoong Pharmaceutical
KSC:069620
27
CountrySouth Korea
IndustryPharmaceuticals
SizeMedium
Full Stock Analysis →
Ilyang Pharmaceutical
KSC:007570
30
CountrySouth Korea
IndustryPharmaceuticals
SizeSmall
Full Stock Analysis →
Sumitomo Dainippon Pharma
TYO:4506
79
CountryJapan
IndustryPharmaceuticals
SizeLarge
Full Stock Analysis →
Dong-A Socio
KSC:000640
85
CountrySouth Korea
IndustryPharmaceuticals
SizeSmall
Full Stock Analysis →
Panion & Bf Biotech
TAI:1760
84
CountryTaiwan
IndustryPharmaceuticals
SizeSmall
Full Stock Analysis →

Make Sense of the Ranks

Every rank runs 1–100 against true peers. Higher is always better.

360° View
1 · Watch OutGood· 100
Value
1 · ExpensiveGood Value· 100
Quality
1 · Weak FundamentalsHigh Quality· 100
Growth
1 · Tough TimesHigh Growth· 100
Safety
1 · High LeverageWell-Financed· 100
Sentiment
1 · SkepticismPositive· 100
Learn More →